MENLO PARK, Calif.--(BUSINESS WIRE)-- Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, ...
OCTAVE-DUO Study To Evaluate Novavax' Vaccine Candidate In Participants With Impaired Immune Systems
(RTTNews) - Novavax, Inc. (NVAX) said its recombinant nanoparticle protein vaccine candidate is being studied in OCTAVE-DUO in the UK to evaluate the safety and immunogenicity of a third COVID-19 ...
A new clinical trial to determine whether a third dose of vaccine will improve the immune response for people who have weakened immune systems is launching in the UK. The study, OCTAVE DUO, will offer ...
A major clinical trial has found that an additional COVID 19 vaccine dose led to the majority of clinically extremely vulnerable people mounting defensive antibodies against Covid-19. New research ...
OXFORD, England, Jun 17, 2014 (BUSINESS WIRE) -- PsiOxus Therapeutics Ltd. (PsiOxus), an award-winning biotechnology company developing innovative new treatments for cancer, today announced the first ...
Atlanta, GA - The dual ACE/NEP inhibitor omapatrilat (Vanlev® - Bristol Myers Squibb (BMS)) showed a 2.17% incidence of angioedema versus 0.68% with enalapril in the new 25000-patient Omapatrilat ...
NEW YORK, NY, May 09, 2023 (GLOBE NEWSWIRE) -- Violet, the first health equity platform, released a new case study today with national behavioral health practice Octave, showing the results of care ...
OXFORD, England--(BUSINESS WIRE)--PsiOxus Therapeutics Ltd. (PsiOxus), the immuno-oncology company, today announced the first treatment of a patient to combine paclitaxel with the oncolytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results